knowledge -WSS

knowledge

author：Wikipedia 2025-09-06 01:41:10 - browse：5643

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

leisure time

Wikipedia

WSS

Scientists unlock the key to scar

Former medical device CEO who sold dummy, plastic parts convicted of fraud

FDA does about

Just how do doctors, lawmakers, and the public define abortion?

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

CDC marks new Covid

entertainment

knowledge

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

What does generative AI mean for health care? We asked experts

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

How to save PrEP access — and even expand it

AstraZeneca loses challenge to Medicare drug price negotiation

Supreme Court strikes down use of affirmative action

Medical device lobby: We're tired of waiting on Medicare coverage

Medicare details structure of new drug price negotiation program

RaDonda Vaught to speak at CommonSpirit event on patient safety

knowledge

Change Healthcare cyberattack prompts Medicare loan program

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Clinical trials giant ICON acquires HumanFirst

The problem with charging patients to message their doctors

Change Healthcare payments predicted restored March 15

leisure time

leisure time

Wikipedia

hotspot